Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology
Reference31 articles.
1. Yu, W. et al. Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance. Leuk. Lymphoma 58, 428–437 (2017).
2. Dick, L. R. & Fleming, P. E. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov. Today 15, 243–249 (2010).
3. Muz, B. et al. Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance. Leuk. Lymphoma 58, 2916–2925 (2017).
4. Vogel, T. P., Milner, J. D. & Cooper, M. A. The Ying and Yang of STAT3 in human disease. J. Clin. Immunol. 35, 615–623 (2015).
5. Barille, S., Bataille, R. & Amiot, M. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur. Cytokine Netw. 11, 546–551 (2000).
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献